What is retatrutide
Retatrutide (LY3437943) is an investigational injectable peptide developed by Eli Lilly. It is a 30-amino-acid analogue with a fatty diacid chain that extends its circulating half-life to approximately five to seven days, enabling once-weekly subcutaneous administration. As of mid-2026, retatrutide has no regulatory approval from the FDA, EMA, or any other authority. All data in this article comes from controlled trial research.
Semaglutide targets one receptor (GLP-1R), tirzepatide targets two (GLP-1R and GIPR), and retatrutide adds a third: the glucagon receptor (GCGR). The glucagon receptor component is the pharmacological basis for Eli Lilly's differentiation claim and the rationale for a multi-arm Phase 3 program. For a contrast with a peptide that has a very different evidence profile, see the BPC-157 research overview, which covers over three decades of primarily rodent-model data with minimal human trial work.
Triple agonist mechanism
Retatrutide binds three G protein-coupled receptors: GLP-1R, GIPR, and GCGR. Each drives a distinct metabolic pathway, and their combined activation is what the research program proposes as the source of the compound's efficacy advantage over dual agonists.
GLP-1R activation promotes glucose-dependent insulin secretion from pancreatic beta cells, slows gastric emptying to extend post-meal satiety, and suppresses appetite through central nervous system signaling. This is the receptor shared by all agents in the incretin class.
GIPR activation augments insulin release in a glucose-dependent manner and, in preclinical models, may reduce appetite and support adipose tissue fat metabolism. The role of GIP receptor agonism in weight management was initially debated, since circulating GIP levels are elevated in obesity and were thought to be metabolically counterproductive. The efficacy of tirzepatide in large Phase 3 trials resolved that question in favor of strong GIPR agonism being net beneficial for weight reduction.
GCGR activation increases hepatic glucose output and, more directly relevant to weight management, activates hormone-sensitive lipase in adipose tissue and promotes hepatic fatty acid oxidation, raising total energy expenditure. In preclinical obesity models, retatrutide produced greater body weight reduction than tirzepatide at calorie-intake-matched conditions, attributed to the thermogenic effect of glucagon receptor signaling rather than reduced food intake alone.
Structural data from a cryo-EM study by Li et al. (2024, Cell Discovery, PMID 39019866) resolved the binding mode of retatrutide at all three receptors simultaneously. Relative to native hormones, retatrutide is 8.9-fold more potent at GIPR, 0.4-fold at GLP-1R, and 0.3-fold at GCGR. The elevated GIPR potency is a deliberate design feature: the researchers propose that strong GIPR activation counteracts the nausea associated with GLP-1R agonism, which is consistent with the tolerability profile observed in clinical trials.
Phase 2 retatrutide research results
The foundational clinical evidence comes from Jastreboff et al. (2023), published in the New England Journal of Medicine (NEJM 389:514-526, PMID 37366315). The Phase 2 trial was double-blind, randomized, and placebo-controlled, enrolling 338 adults with a BMI of at least 30, or 27 to under 30 with at least one weight-related comorbidity, without type 2 diabetes. Six active dose groups (1 mg; two 4-mg variants; two 8-mg variants; and 12 mg) ran for 48 weeks alongside a placebo arm.
Least-squares mean percentage change in body weight at week 48:
- 1 mg: -8.7%
- Combined 4 mg groups: -17.1%
- Combined 8 mg groups: -22.8%
- 12 mg: -24.2%
- Placebo: approximately -2.1%
All active doses met the primary endpoint versus placebo. The 24.2% result at 48 weeks exceeded the top-line efficacy seen with tirzepatide (20.9% at 72 weeks) and semaglutide (14.9% at 68 weeks) in their respective Phase 3 approval trials. Cross-trial comparisons have the usual caveats: different populations, durations, and titration schedules mean they are approximations, not controlled findings.
Gastrointestinal adverse events were the most commonly reported: nausea, vomiting, and diarrhea, consistent with the class profile of GLP-1-based agents. Events were most frequent during dose escalation and decreased over time. No safety signal outside the expected class pattern appeared in the Phase 2 data.
Phase 3 TRIUMPH program
Eli Lilly launched the TRIUMPH Phase 3 program based on the Phase 2 results, registering several parallel trials on ClinicalTrials.gov across distinct patient populations.
NCT05929066 (TRIUMPH-1) enrolled 2,339 adults with obesity or overweight alongside at least one cardiometabolic comorbidity, without diabetes. Top-line results disclosed in 2026 showed 28.3% mean weight loss at 72 weeks and 30.3% at 104 weeks in the 12 mg group among participants with a baseline BMI of at least 35. All primary and key secondary endpoints were met.
NCT05929079 (TRIUMPH-2) targets participants with type 2 diabetes and obesity or overweight. NCT05882045 (TRIUMPH-3) targets participants with obesity and established cardiovascular disease. NCT06662383 is a direct head-to-head comparison of retatrutide against tirzepatide in adults with obesity; results have not yet been disclosed.
The TRIUMPH-1 result at 104 weeks (30.3%) falls within the 25-35% weight reduction range typically associated with bariatric surgery. Whether this result holds in a broader population with lower baseline BMI, and what the long-term cardiovascular safety profile shows, are the open questions the ongoing TRIUMPH arms are designed to answer.
Comparison with semaglutide and tirzepatide
Three incretin-class agents now anchor the published evidence base, each representing an additional receptor target:
Semaglutide (GLP-1 mono-agonist, Wegovy): Wilding et al. (2021), STEP 1, n=1,961, NEJM 384:989-1002. Mean weight loss: -14.9% at 68 weeks. FDA approved for chronic weight management.
Tirzepatide (GLP-1/GIP dual agonist, Zepbound): Jastreboff et al. (2022), SURMOUNT-1, n=2,539, NEJM 387:205-216. Mean weight loss: -20.9% at 72 weeks (15 mg dose). FDA approved for chronic weight management.
Retatrutide (GLP-1/GIP/glucagon triple agonist): Phase 2 (n=338), -24.2% at 48 weeks; Phase 3 TRIUMPH-1 (n=2,339), -30.3% at 104 weeks. No regulatory approval as of mid-2026.
The pattern across this sequence is consistent with each additional receptor contributing measurable efficacy. The controlled head-to-head trial (NCT06662383) is the appropriate tool for confirming whether the superiority seen in cross-trial extrapolation holds under matched conditions. Until those results are available, the data is directionally consistent but not definitive on relative efficacy.
Storage and handling for research use
Retatrutide in research supply is a lyophilized powder for subcutaneous administration. Standard peptide handling applies: unreconstituted vials store at -20°C, and repeated freeze-thaw cycles degrade the compound. After reconstitution with bacteriostatic water, solutions refrigerate at 2-8°C and should be used within 28 days under standard research protocols.
For researchers in Indonesia and Southeast Asia, cold-chain management is the primary practical concern. Ambient temperatures in Bali and other parts of Indonesia regularly exceed 30°C, which can accelerate degradation even in lyophilized form if cold storage is interrupted during transit or local handling. The lyophilized peptide storage guide covers two-tier cold storage setups and common failure points specific to tropical conditions.
For volume and dose calculations in research protocols, the peptide dosing calculator on this site handles standard reconstitution and syringe-draw math. Retatrutide is listed in the compound catalog for research procurement across Bali, Jakarta, Surabaya, and Yogyakarta.